Advertisement


Martin H. Schuler, MD, on Gastric and GEJ Adenocarcinoma: Results of the FAST Study (German Language Version)

2016 ESMO Congress

Advertisement

Martin H. Schuler, MD, of the University Hospital Essen, discusses in German findings from this phase II trial of epirubicin, oxaliplatin, and capecitabine with or without the antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ disease. (Abstract 614O)



Related Videos

Colorectal Cancer

Derek J. Jonker, MD, on Colorectal Cancer: Results From the CCTG/AGITG CO.23 Trial

Derek J. Jonker, MD, of The Ottawa Hospital Cancer Centre, discusses phase III study findings on napabucasin vs placebo in patients with pretreated advanced colorectal cancer. (Abstract 454O)

Prostate Cancer

Christopher J. Sweeney, MBBS, on Prostate Cancer: CHAARTED Trial Follow-up

Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how long-term study results showed no survival benefit in men with ogliometastatic prostate cancer. (Abstract 720PD)

Skin Cancer

Paolo A. Ascierto, MD, on Metastatic Melanoma: Ipilimumab Study Results

Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori–Fondazione Pascale, discusses overall survival and safety results from a phase III trial of ipilimumab at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma. (Abstract 1106O)

Breast Cancer

Judith Balmaña, MD, PhD, on Metastatic Breast Cancer: Study Results on Lurbinectedin (Spanish Language Version)

Judith Balmaña, MD, PhD, of Vall d’Hebron University Hospital, discusses in Spanish the findings of a single-agent phase II trial on the antitumor activity of lurbinectedin in BRCA1/2-associated metastatic breast cancer patients. (Abstract 223O)

Breast Cancer

Matthew J. Ellis, PhD, MB, BCh, on Breast Cancer: Results of the FALCON Trial

Matthew J. Ellis, PhD, MB, BCh, of the Baylor College of Medicine, discusses phase III study findings on fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced disease. (Abstract LBA14)

Advertisement

Advertisement




Advertisement